GT Biopharma shares surge 11.18% after-hours after submitting IND for GTB-5550 TriKE targeting solid tumors.

GT Biopharma Inc. surged 11.18% in after-hours trading following the announcement of its investigational new drug (IND) submission for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for solid tumor cancers. The submission, made in December 2025, marks the company’s advancement into clinical development for a second TriKE-based therapy. The news highlights GT Biopharma’s expansion into the $362 billion global solid tumor market and underscores its pipeline progress, with plans to initiate a Phase 1 basket trial in 2026. Additionally, the company reported a preliminary cash balance of $7 million, extending its runway into Q3 2026, which alleviates near-term financial concerns. The IND submission and positive cash flow projections align with the stock’s sharp after-hours rally, reflecting investor optimism about the therapy’s potential and the company’s strategic momentum.